Literature DB >> 34289240

Glycolysis downregulation is a hallmark of HIV-1 latency and sensitizes infected cells to oxidative stress.

Iart Luca Shytaj1,2,3, Francesco Andrea Procopio4, Mohammad Tarek5, Irene Carlon-Andres6,7,8, Hsin-Yao Tang9, Aaron R Goldman9, MohamedHusen Munshi10, Virender Kumar Pal10, Mattia Forcato11, Sheetal Sreeram12, Konstantin Leskov12, Fengchun Ye12, Bojana Lucic2,13, Nicolly Cruz3, Lishomwa C Ndhlovu14, Silvio Bicciato11, Sergi Padilla-Parra6,7,8, Ricardo Sobhie Diaz3, Amit Singh10, Marina Lusic2,13, Jonathan Karn12, David Alvarez-Carbonell12, Andrea Savarino1.   

Abstract

HIV-1 infects lymphoid and myeloid cells, which can harbor a latent proviral reservoir responsible for maintaining lifelong infection. Glycolytic metabolism has been identified as a determinant of susceptibility to HIV-1 infection, but its role in the development and maintenance of HIV-1 latency has not been elucidated. By combining transcriptomic, proteomic, and metabolomic analyses, we here show that transition to latent HIV-1 infection downregulates glycolysis, while viral reactivation by conventional stimuli reverts this effect. Decreased glycolytic output in latently infected cells is associated with downregulation of NAD+ /NADH. Consequently, infected cells rely on the parallel pentose phosphate pathway and its main product, NADPH, fueling antioxidant pathways maintaining HIV-1 latency. Of note, blocking NADPH downstream effectors, thioredoxin and glutathione, favors HIV-1 reactivation from latency in lymphoid and myeloid cellular models. This provides a "shock and kill effect" decreasing proviral DNA in cells from people living with HIV/AIDS. Overall, our data show that downmodulation of glycolysis is a metabolic signature of HIV-1 latency that can be exploited to target latently infected cells with eradication strategies.
© 2021 The Authors. Published under the terms of the CC BY 4.0 license.

Entities:  

Keywords:  HIV-1 latency; glycolysis; oxidative stress; pentose cycle; pyrimidine metabolism

Year:  2021        PMID: 34289240     DOI: 10.15252/emmm.202013901

Source DB:  PubMed          Journal:  EMBO Mol Med        ISSN: 1757-4676            Impact factor:   12.137


  12 in total

1.  Recruitment of the CoREST transcription repressor complexes by Nerve Growth factor IB-like receptor (Nurr1/NR4A2) mediates silencing of HIV in microglial cells.

Authors:  Fengchun Ye; David Alvarez-Carbonell; Kien Nguyen; Konstantin Leskov; Yoelvis Garcia-Mesa; Sheetal Sreeram; Saba Valadkhan; Jonathan Karn
Journal:  PLoS Pathog       Date:  2022-07-07       Impact factor: 7.464

Review 2.  Innate metabolic responses against viral infections.

Authors:  Clovis S Palmer
Journal:  Nat Metab       Date:  2022-10-20

Review 3.  Anomalous HIV-1 RNA, How Cap-Methylation Segregates Viral Transcripts by Form and Function.

Authors:  Kathleen Boris-Lawrie; Gatikrushna Singh; Patrick S Osmer; Dora Zucko; Seth Staller; Xiao Heng
Journal:  Viruses       Date:  2022-04-29       Impact factor: 5.818

4.  Genome-scale metabolic models for natural and long-term drug-induced viral control in HIV infection.

Authors:  Anoop T Ambikan; Sara Svensson-Akusjärvi; Shuba Krishnan; Maike Sperk; Piotr Nowak; Jan Vesterbacka; Anders Sönnerborg; Rui Benfeitas; Ujjwal Neogi
Journal:  Life Sci Alliance       Date:  2022-05-10

5.  Peripheral blood CD4+CCR6+ compartment differentiates HIV-1 infected or seropositive elite controllers from long-term successfully treated individuals.

Authors:  Sara Svensson Akusjärvi; Shuba Krishnan; Bianca B Jütte; Anoop T Ambikan; Soham Gupta; Jimmy Esneider Rodriguez; Ákos Végvári; Maike Sperk; Piotr Nowak; Jan Vesterbacka; J Peter Svensson; Anders Sönnerborg; Ujjwal Neogi
Journal:  Commun Biol       Date:  2022-04-13

6.  Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial.

Authors:  Marcella Vassão de Almeida Baptista; Laís Teodoro da Silva; Sadia Samer; Telma Miyuki Oshiro; Iart Luca Shytaj; Leila B Giron; Nathalia Mantovani Pena; Nicolly Cruz; Gisele Cristina Gosuen; Paulo Roberto Abrão Ferreira; Edécio Cunha-Neto; Juliana Galinskas; Danilo Dias; Maria Cecilia Araripe Sucupira; Cesar de Almeida-Neto; Reinaldo Salomão; Alberto José da Silva Duarte; Luís Mário Janini; James R Hunter; Andrea Savarino; Maria Aparecida Juliano; Ricardo Sobhie Diaz
Journal:  AIDS Res Ther       Date:  2022-01-12       Impact factor: 2.250

7.  Influenza Virus Down-Modulates G6PD Expression and Activity to Induce Oxidative Stress and Promote Its Replication.

Authors:  Marta De Angelis; Donatella Amatore; Paola Checconi; Alessandra Zevini; Alessandra Fraternale; Mauro Magnani; John Hiscott; Giovanna De Chiara; Anna Teresa Palamara; Lucia Nencioni
Journal:  Front Cell Infect Microbiol       Date:  2022-01-06       Impact factor: 5.293

Review 8.  Therapeutic Metabolic Reprograming Using microRNAs: From Cancer to HIV Infection.

Authors:  Mark S Gibson; Cláudia Noronha-Estima; Margarida Gama-Carvalho
Journal:  Genes (Basel)       Date:  2022-01-29       Impact factor: 4.096

9.  Immunometabolic Reprogramming in Response to HIV Infection Is Not Fully Normalized by Suppressive Antiretroviral Therapy.

Authors:  Pragney Deme; Leah H Rubin; Danyang Yu; Yanxun Xu; Gertrude Nakigozi; Noeline Nakasujja; Aggrey Anok; Alice Kisakye; Thomas C Quinn; Steven J Reynolds; Richard Mayanja; James Batte; Maria J Wawer; Ned C Sacktor; Deanna Saylor; Norman J Haughey
Journal:  Viruses       Date:  2022-06-15       Impact factor: 5.818

Review 10.  Hallmarks of Metabolic Reprogramming and Their Role in Viral Pathogenesis.

Authors:  Charles N S Allen; Sterling P Arjona; Maryline Santerre; Bassel E Sawaya
Journal:  Viruses       Date:  2022-03-14       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.